ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021
Head-to-Head Comparison of
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Trial
- 4D nanoimaging-guided smart therapeutics: spatiotemporal control of disease microenvironments.RSC advances · 2026Review
- Anatomical Refinement of Pelvic Lymphadenectomy in Extraperitoneal Radical Prostatectomy Based on a Constant Venous Landmark.Journal of clinical medicine · 2025Article
- Advanced Nanomaterials for Cancer Therapy: Gold, Silver, and Iron Oxide Nanoparticles in Oncological Applications.Advanced healthcare materials · 2025Review
- Advances in molecular imaging and targeted therapeutics for lymph node metastasis in cancer: a comprehensive review.Journal of nanobiotechnology · 2024Review
- Recurrent prostate cancer: combined role for MRI and PSMA-PET inEuropean radiology · 2024Article
- Advancing MRI with magnetic nanoparticles: a comprehensive review of translational research and clinical trials.Nanoscale advances · 2024Review
- Revolutionizing lymph node metastasis imaging: the role of drug delivery systems and future perspectives.Journal of nanobiotechnology · 2024Review
- Advancements and Challenges in the Application of Metal-Organic Framework (MOF) Nanocomposites for Tumor Diagnosis and Treatment.International journal of nanomedicine · 2024Review
- Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects.International journal of nanomedicine · 2024Review
- Functional roles of magnetic nanoparticles for the identification of metastatic lymph nodes in cancer patients.Journal of nanobiotechnology · 2023Review
- Prediction of pelvic lymph node metastases and PSMA PET positive pelvic lymph nodes with multiparametric MRI and clinical information in primary staging of prostate cancer.European journal of radiology open · 2023Article
- Improving diagnostic efficacy of primary prostate cancer with combinedFrontiers in oncology · 2023Article
- IONPs-Based Medical Imaging in Cancer Care: Moving Beyond Traditional Diagnosis and Therapeutic Assessment.International journal of nanomedicine · 2023Review
- Nanoparticle Diagnostics and Theranostics in the Clinic.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Review
- The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.Nature reviews. Urology · 2022Review
- The role of MRI in prostate cancer: current and future directions.Magma (New York, N.Y.) · 2022Review
- Molecular imaging in oncology: Current impact and future directions.CA: a cancer journal for clinicians · 2022Review
- Validation of In Vivo Nodal Assessment of Solid Malignancies with USPIO-Enhanced MRI: A Workflow Protocol.Methods and protocols · 2022Article
- Advanced nanomaterial for prostate cancer theranostics.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate assessment of lymph node (LN) metastases in prostate cancer (PCa) patients is critical for prognosis and patient management. Both prostate-specific membrane antigen (PSMA) PET/CT and ferumoxtran-10 nanoparticle-enhanced MRI (nano-MRI) are imaging modalities with high potential to identify LN metastases in PCa patients. The aim of this study was to compare the results of these imaging technologies in terms of characteristics and anatomic localization of suspicious LNs in order to assess the feasibility of their complementary use for imaging in PCa patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.